Actively Recruiting
Evaluating the Safety and Efficacy of Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Led by Tanta University · Updated on 2025-11-25
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver condition characterized by excess fat buildup in the liver not caused by alcohol or other known factors. This condition is a major health concern worldwide, especially in developed countries. The study aims to evaluate the safety and effectiveness of cilostazol, a drug that may improve liver fat, in adults diagnosed with NAFLD. Participants will be randomly assigned to one of two groups. One group will receive standard therapy, which includes regular exercise and calorie restriction, along with a placebo for three months. The other group will receive the same standard therapy plus cilostazol at a dose of 100 mg twice daily. The study will last for three months to assess the effects of these treatments. During the study, researchers will monitor changes in liver fat levels using ultrasound and assess fibrosis risk scores. Participants will follow prescribed exercise routines and dietary plans. Safety and treatment effects will be closely observed throughout the study period, which lasts three months. This trial is sponsored by Tanta University and includes adults aged 18 to 60 years with diagnosed fatty liver disease.
CONDITIONS
Brief Title
Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults over 18 years old diagnosed with fatty liver by ultrasound
- Both male and female patients
- Able to follow prescribed exercise and dietary plans
- Willing to participate for the full 3-month study duration
You will not qualify if you...
- Pregnant or breastfeeding women
- Men consuming more than 30 g and women consuming more than 20 g of alcohol daily
- Patients with other chronic liver diseases such as viral hepatitis, drug-induced hepatitis, or autoimmune hepatitis
- Patients with chronic kidney disease, parathyroid disorders, or congestive heart failure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 months
Participants receive either cilostazol plus standard conventional therapy or placebo plus standard conventional therapy, including regular exercise and calorie restriction.
Visits scheduled during the 3-month treatment period
Trial Site Locations
Total: 1 location
1
Mostafa Bahaa
Damietta, New Damietta, Egypt, 34518
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here